Apheris released OpenBind-0, an open co-folding model that ships with 717 ligand-bound structures from fragment-to-hit campaigns on three real discovery targets.

Apheris delivers enterprise-grade AI applications for drug discovery, designed for pharma companies to run and customize securely within their own IT environments. By keeping all data local, organizations maintain full sovereignty over IP-sensitive assets. These local deployments also serve as the foundation for Apheris-hosted federated data networks, where pharma companies collaboratively train and benchmark models on proprietary datasets to unlock more robust and generalizable models for drug discovery.